1 (CAI) (NSC609974) is both antiangiogenic and
antimetastatic.
2 However, the mechanism of the
antimetastatic actions of KiSS1 and its G-protein-couple
3 tudies in vivo, only a few have shown potent
antimetastatic activities in clinical trials.
4 umor immune responses that provide effective
antimetastatic activities in preclinical studies.
5 ckade of PD-1/PD-L interactions enhanced the
antimetastatic activities of alphaGalCer.
6 otentiated the antitumor, anti-invasive, and
antimetastatic activities of docetaxel both in culture a
7 maturation; (b) augmented the antitumor and
antimetastatic activities of programmed cell death 1-bas
8 molecules bearing the tumor-sensitizing and
antimetastatic activities of TAT-RasGAP317-326.
9 ed micelles displayed superior antitumor and
antimetastatic activities without impairing safety.
10 nhibitor that has both antiproliferative and
antimetastatic activities.
11 imulate proapoptotic, antiproliferative, and
antimetastatic activities.
12 rapid preclinical testing of compounds with
antimetastatic activity and highlighted CDK12 as a poten
13 Sunitinib maintained its antiangiogenic and
antimetastatic activity but lost its direct antitumor ef
14 emonstrates that Monensin exhibits potential
antimetastatic activity by disrupting the promigratory G
15 ese results indicate that losartan can exert
antimetastatic activity by inhibiting CCR2 signaling and
16 ally type I NKT cells, inhibit liver NK-cell
antimetastatic activity by the production of IL-10.
17 iral pyrrolidines with antiproliferative and
antimetastatic activity in a murine model of colon carci
18 ferred NKT cells dramatically enhanced their
antimetastatic activity in mice.
19 using a monoclonal antibody (2G8) has potent
antimetastatic activity in orthotopic human tumor xenogr
20 DX-8951f also demonstrated
antimetastatic activity in the late-stage model, signifi
21 gated Ir complexes revealed that the highest
antimetastatic activity in TNBC cells is exhibited by co
22 factors and displayed improved antitumor and
antimetastatic activity in vivo compared with the earlie
23 ructural components of CD81 required for the
antimetastatic activity induced by 5A6.
24 The
antimetastatic activity is epitope specific, as another
25 Taken together, our findings illustrate the
antimetastatic activity of 6BIO on the basis of its abil
26 Furthermore, the profound
antimetastatic activity of NK cells was equally effectiv
27 Potential mechanisms for
antimetastatic activity of synthetic glycoamines may inc
28 The significant
antimetastatic activity of synthetic glycoamines was det
29 n CS-682-treated animals correlated with the
antimetastatic activity of this compound.
30 sting that each gene appeared to produce its
antimetastatic activity through a common antiangiogenic
31 bited experimental lung metastasis, and this
antimetastatic activity was compromised in mice depleted
32 was dependent on CD8(+) T cells, whereas its
antimetastatic activity was dependent on host CD73 expre
33 nalogue, metarrestin, which has shown potent
antimetastatic activity with improved survival in rodent
34 asculature resulted in a 15-fold increase in
antimetastatic activity without producing drug-associate
35 development of resistance and with enhanced
antimetastatic activity, thus ultimately resulting in im
36 ontain other bioactive ingredients that have
antimetastatic activity.
37 are cytotoxic lymphocytes displaying strong
antimetastatic activity.
38 meric CQ (pCQ) as a macromolecular drug with
antimetastatic activity.
39 showed that all isolated compounds had weak
antimetastatic activity.
40 killer (NK) cells have potent antitumor and
antimetastatic activity.
41 T) shows potent and selective anticancer and
antimetastatic activity.
42 HSCN-NH2 may be a potent antitumorigenic and
antimetastatic agent for postsurgical use prior to exten
43 s high-affinity TFD100 should be a promising
antimetastatic agent for the treatment of various cancer
44 e demonstrated that CS-682 is an efficacious
antimetastatic agent that significantly prolongs surviva
45 nt for tumor suppression and functions as an
antimetastatic agent.
46 The III1-C peptide is an antiangiogenic and
antimetastatic agent.
47 tential of Ap44mSe as a selective anticancer/
antimetastatic agent.
48 lanation directly supporting genistein as an
antimetastatic agent.
49 ical applications as potential antitumor and
antimetastatic agent.
50 omo-indirubin-3'-oxime (6BIO) as a promising
antimetastatic agent.
51 ell migration and their implied potential as
antimetastatic agents for human cancers has garnered sig
52 oprine and related compounds could be potent
antimetastatic agents for Vav1-positive pancreatic tumor
53 ted deaths, but the development of effective
antimetastatic agents has been hampered by the paucity o
54 st that these analogs have promise as potent
antimetastatic agents in lung cancer.
55 Critical assessment of these
antimetastatic agents is warranted, because they may def
56 and suggest that HAS2 inhibitors can act as
antimetastatic agents that disrupt a paracrine growth fa
57 for future drug combination approaches with
antimetastatic agents to improve outcomes and reduce res
58 been an important lead in the development of
antimetastatic agents.
59 re highly sought as potential anticancer and
antimetastatic agents.
60 o the potential utility of p38 inhibitors as
antimetastatic agents.
61 uld also improve the screening efficiency of
antimetastatic agents.
62 ns for TLR5 agonists as hepatoprotective and
antimetastatic agents.
63 and as orally active, bioavailable, and safe
antimetastatic agents.
64 ecroptosis and as a new promising target for
antimetastatic and advanced-stage cancer therapies.
65 with 4a in vivo on mice, suggesting putative
antimetastatic and analgesic activities of this compound
66 In conclusion, S247 demonstrated significant
antimetastatic and antiangiogenic activity and impaired
67 acin, might have therapeutic applications as
antimetastatic and antiangiogenic agents.
68 suggest that ROCK inhibitors would be useful
antimetastatic and antiangiogenic chemotherapeutic agent
69 performed to characterize the effects of an
antimetastatic and antiangiogenic molecule, carboxyamido
70 Importantly, they demonstrated
antimetastatic and antiangiogenic properties without in
71 of intracellular signaling and exhibits both
antimetastatic and antitumorigenic properties.
72 polyamine component and was shown to be both
antimetastatic and cytotoxic to human L3.6pl pancreatic
73 -BR is a promising antimelanoma therapy with
antimetastatic and immunomodulatory activities warrantin
74 l candidate function underlying the putative
antimetastatic and oncogenic activities of NM23-H1.
75 rough binding to the CT element and that its
antimetastatic and other reported functions are likely d
76 r of ALDOA-gamma-actin binding that produced
antimetastatic and survival benefits in a xenograft mode
77 nth., Rutaceae), exhibits antiproliferative,
antimetastatic,
and apoptotic activities through a poorl
78 multifunctional serpin with antitumorigenic,
antimetastatic,
and differentiating activities.
79 esults in antiproliferative, antiangiogenic,
antimetastatic,
and immunostimulatory effects.
80 as also recognized by a previously described
antimetastatic antibody, mAb 1A5.
81 t that inhibition of MET may be an effective
antimetastatic approach to treat cancers with p53 mutati
82 organ, and discusses opportunities for novel
antimetastatic approaches for cancer therapy.
83 rs that may play a role in mediating the 5A6
antimetastatic attributes, including integrins and trans
84 e lung by tumor-secreted chemokines build an
antimetastatic barrier with loss of neutrophil chemokine
85 alloproteinase (MMP) inhibitors has hindered
antimetastatic cancer drug discovery.
86 Ks are therefore a promising drug target for
antimetastatic cancer treatments that could supplement a
87 ortant therapeutic target for development of
antimetastatic cancer treatments.
88 The selective antitumor and
antimetastatic chelator di-2-pyridylketone 4,4-dimethyl-
89 which there is a pressing need to find novel
antimetastatic compounds.
90 e lymphoid cells (trILC1s), is essential for
antimetastatic defense.
91 hat are critical to the body's antitumor and
antimetastatic defense.
92 results permit the conformational design of
antimetastatic disintegrins.
93 veloped an animal model suited to evaluating
antimetastatic drug efficacy.
94 We also used the device to screen
antimetastatic drugs for their inhibition of mesenchymal
95 es, a specific category of anti-invasion and
antimetastatic drugs is missing.
96 human PCa metastasis well suited for testing
antimetastatic drugs.
97 -analysis pipeline for the identification of
antimetastatic drugs.
98 zyme B in vivo, strongly suggesting that the
antimetastatic effect of A2A blockade was due to enhance
99 However, the
antimetastatic effect of AdCMVIFN-beta was not directly
100 In contrast to the
antimetastatic effect of AMG487, local growth of 66.1 ma
101 lecular evidence that is associated with the
antimetastatic effect of berberine by showing a nearly c
102 Particularly, the
antimetastatic effect of combined Wee1/ATR inhibition an
103 f a CD8(+) T-cell response, which exert both
antimetastatic effect of entolimod and establishment of
104 nd ROCK are additional key components of the
antimetastatic effect of kisspeptins.
105 The IL-2 mutant shows a higher
antimetastatic effect than does wtIL-2 in several transp
106 that combined therapy also had a more potent
antimetastatic effect than each modality alone.
107 stasis, targeted delivery of Dox produced an
antimetastatic effect.
108 itro suggesting a possible mechanism for the
antimetastatic effect.
109 tanoid product of COX-1 responsible for this
antimetastatic effect.
110 this pair of compounds exhibits a pronounced
antimetastatic effect.
111 ent corresponded to a significantly enhanced
antimetastatic effect: lung nodules were reduced by 7- t
112 Antimetastatic effects along with stimulation of NK cell
113 Because its
antimetastatic effects are mediated by binding to VEC ra
114 Many of their
antimetastatic effects could be the result of their abil
115 gs demonstrate the capacity of ERB to elicit
antimetastatic effects in highly aggressive inflammatory
116 D40 Ab resulted in substantial antitumor and
antimetastatic effects in three tumor models.
117 show that miR-520f exerts anti-invasive and
antimetastatic effects in vitro and in vivo, warranting
118 in vitro, and that MN-15 and MN-3 Fabs have
antimetastatic effects in vivo, resulting in improved su
119 ls by anti-asialo GM1 antibody abrogated the
antimetastatic effects of AdCMVIFN-beta.
120 RDX, and RhoA was capable of overriding the
antimetastatic effects of ectopically expressed miR-31 i
121 Thus, the potent
antimetastatic effects of GRN163L may be related, in par
122 hether the apoptotic, antiproliferative, and
antimetastatic effects of guggulsterone (GS), a farnesoi
123 The antivascular, antitumor, and
antimetastatic effects of mpJX-594 were amplified by con
124 Furthermore, testing the
antimetastatic effects of the investigated Ir complexes
125 Our study supports the hypothesis that the
antimetastatic effects of zoledronic acid may be through
126 MMP9 appear to mediate the antiinvasive and
antimetastatic effects produced by FKBP gene expression.
127 These antitumor and
antimetastatic effects were comparable with those result
128 tos-1-yl)-L-leucine did not have significant
antimetastatic effects, and no reduction in metastasis i
129 colony formation and demonstrated heritable
antimetastatic effects, which were dependent on AP-2a.
130 ellular matrix and to its reported antitumor/
antimetastatic effects.
131 le, and manifest complementary antitumor and
antimetastatic effects.
132 E-cad-positive cells, the IGF-IR may produce
antimetastatic effects.
133 which can produce significant antitumor and
antimetastatic effects.
134 ellular immunity that may have antitumor and
antimetastatic effects.
135 Contrastingly, B cells can also exhibit
antimetastatic effects.
136 elease and enhanced drug dispersion to exert
antimetastatic effects.
137 ets, Robo2 and P2ry1, also have demonstrable
antimetastatic effects.
138 trioxifene represents a SERM with potential
antimetastatic efficacy for the treatment of androgen-in
139 Studies of
antimetastatic efficacy in man are warranted and are und
140 concentrations of genistein associated with
antimetastatic efficacy in preclinical models are achiev
141 The
antimetastatic efficacy of CS-682 and its p.o. availabil
142 also provide initial preclinical data on the
antimetastatic efficacy of recently discovered small-mol
143 We determined the antitumor and
antimetastatic efficacy of the camptothecin analogue DX-
144 nts have been developed and tested for their
antimetastatic efficacy.
145 Studies on the
antimetastatic function of KiSS1 and GPR54 largely focus
146 ty group AT-hook 2 gene (HMGA2) mediates the
antimetastatic function of TTF-1.
147 y Khawaled and colleagues points to a direct
antimetastatic function of WW domain-containing oxidored
148 Gr-1(int) myeloid cells that promote NK cell
antimetastatic function.
149 ring mice to identify novel antiinvasive and
antimetastatic functions for Fkbp8, and subsequently for
150 ce, however, that CD8(+) T cells have unique
antimetastatic functions in various steps of the metasta
151 mental evidence that CAV1 may function as an
antimetastatic gene in malignant melanoma.
152 equired for stimulation of the antitumor and
antimetastatic immune response by B7.2-IgG/TC.
153 ffector responses are required for effective
antimetastatic immunity, whether tissue-resident immune
154 strate a local immune circuit to confer host
antimetastatic immunity.
155 t antiproliferative, prodifferentiating, and
antimetastatic/
invasive effects on prostatic epithelial
156 This study uncovers an
antimetastatic mechanism involving AKR1B10-mediated PP2A
157 EMSY amplification and miR-31 expression, an
antimetastatic microRNA, in the METABRIC cohort of human
158 exerts its metastatic potential by silencing
antimetastatic miR-200 through direct targeting of the T
159 demethylation of a regulatory region of the
antimetastatic miRNA cluster mir-200ba429, leading to th
160 Yet its
antimetastatic nature has eluded a thorough mechanistic
161 alpha promoted the development of a vascular
antimetastatic niche characterized by liver sinusoidal e
162 Surprisingly, the
antimetastatic outcome of MMP9 ablation seemed to be dep
163 dditional depletion of NK cells reverts this
antimetastatic phenotype.
164 74, which elicited significant antitumor and
antimetastatic potential in several primary and metastat
165 To evaluate the
antimetastatic potential of genistein, we developed an a
166 In the current study, we investigated the
antimetastatic potential of penfluridol, an antipsychoti
167 Antimetastatic properties of covalently inactivated VIIa
168 The antitumor and
antimetastatic properties of SCF may be useful in treati
169 within the C^N scaffold strongly impact the
antimetastatic properties of these complexes in TNBC cel
170 al are known to possess antiproliferative or
antimetastatic properties.
171 th anti-inflammatory, antiproliferative, and
antimetastatic properties.
172 flammatory, immunoregulatory, antitumor, and
antimetastatic properties.
173 tastasis is essential for the development of
antimetastatic regimens.
174 iltrating activated NK cells and an enhanced
antimetastatic response.
175 Here, we revealed an unexpected
antimetastatic role for myeloid-derived PROS1: suppressi
176 p53 (TP53) family member p63 (TP63) plays an
antimetastatic role through its minor epithelial isoform
177 iating cells need to overcome organ-specific
antimetastatic signals in order to undergo reactivation.
178 reby stimulating its ability to activate the
antimetastatic small GTPase RhoB.
179 rug platform suitable for use in combination
antimetastatic strategies and potential use in cytoplasm
180 view, we provide a brief overview of current
antimetastatic strategies that show clinical efficacy an
181 ase progression and an attractive target for
antimetastatic strategies to reduce colon cancer mortali
182 d paves the way for the development of novel
antimetastatic strategies.
183 fy TNFalpha and TGFbeta1 dual blockade as an
antimetastatic strategy in solid tumors.
184 asis but might be targeted by curcumin as an
antimetastatic strategy.
185 NPY1R signaling is a previously unidentified
antimetastatic target in PC.
186 cell invasion, and may provide an important
antimetastatic target.
187 s a novel biomarker of tumor progression and
antimetastatic therapeutic agent.
188 tastasis in animal model systems and suggest
antimetastatic therapeutic potential of the TbetaRI-I.
189 eutrophil protease-Tsp-1 axis as a potential
antimetastatic therapeutic target.
190 630) holds promise for the development of an
antimetastatic therapeutic that blocks tumor cell dediff
191 ovide important insights to develop rational
antimetastatic therapeutics.
192 ity and for the rapid screening of potential
antimetastatic therapeutics.
193 rtality, there nonetheless remains a lack of
antimetastatic therapies that are clinically available.
194 er metastasis and suggest new strategies for
antimetastatic therapies that target the beta-adrenergic
195 promising targets of future mechanism-driven
antimetastatic therapies, which may prove useful to syne
196 that GPVI represents a promising target for
antimetastatic therapies.
197 are prometastatic and represent targets for
antimetastatic therapies.
198 may serve as targets for antiangiogenic and
antimetastatic therapies.
199 therefore, critical for developing effective
antimetastatic therapies.
200 sis and unmasking a potential new target for
antimetastatic therapies.
201 screening strategies needed to develop novel
antimetastatic therapies.
202 represents a promising molecular target for
antimetastatic therapies.
203 ion opening the opportunity to develop novel
antimetastatic therapies.
204 nce knowledge about metastasis and candidate
antimetastatic therapies.
205 tudy, we provide preclinical evidence for an
antimetastatic therapy based on targeting integrin beta3
206 e activity represents a promising target for
antimetastatic therapy for several types of tumor.
207 antagonists may offer significant value for
antimetastatic therapy in patients with colon cancer.
208 ay represent a promising candidate for novel
antimetastatic therapy in patients with UM.
209 se signaling pathways could prove useful for
antimetastatic therapy.
210 ms and may become markers and/or targets for
antimetastatic therapy.
211 lopment of anti-FGFR inhibitors as potential
antimetastatic therapy.
212 tastasis and identify a potential target for
antimetastatic therapy.
213 ociated isoforms are potential candidates in
antimetastatic therapy.
214 ssion and a promising therapeutic target for
antimetastatic therapy.
215 d heparanase and reciprocal up-regulation of
antimetastatic tissue inhibitors of matrix metalloprotei
216 resent one of the first points of action for
antimetastatic treatment.
217 , it is the right time to enter a new era of
antimetastatic treatment.
218 Two examples include the
antimetastatic,
tumor suppressor genes, desmocollin 3 (D
219 a polymeric form of fibronectin is strongly
antimetastatic when administered systemically to tumor-b